NEO vs SLNO vs RARE vs ACAD vs LGND

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 60.

4% revenue growth year-over-year, versus 10. 1% for NeoGenomics, Inc. (NEO). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 2x versus Soleno Therapeutics, Inc. at 135. 9x. On forward P/E, Soleno Therapeutics, Inc. is actually cheaper at 13. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +107.

7%, compared to -76. 3% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: LGND returned +126. 0% versus SLNO's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Soleno Therapeutics, Inc.

(SLNO) is the lower-risk stock at 0. 98β versus Ultragenyx Pharmaceutical Inc. 's 1. 43β — meaning RARE is approximately 47% more volatile than SLNO relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 56% for NeoGenomics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 60.

4% versus 10. 1% for NeoGenomics, Inc. (NEO). On earnings-per-share growth, the picture is similar: Ligand Pharmaceuticals Incorporated grew EPS 28. 9% year-over-year, compared to -35. 5% for NeoGenomics, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning 46.

4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 46. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LGND leads at 17. 6% versus -79. 5% for RARE. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Soleno Therapeutics, Inc.

(SLNO) trades at 13. 9x forward P/E versus 61. 9x for NeoGenomics, Inc. — 48. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 98. 6% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

03), +126. 0% 10Y return). Both have compounded well over 10 years (LGND: +126. 0%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NEO is a small-cap quality compounder stock; SLNO is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; LGND is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.